Výsledky vyhledávání - "David L. Ebel"

Effects of Aspirin When Added to the Prostaglandin D2Receptor Antagonist Laropiprant on Niacin-Induced Flushing Symptoms

Autor: Fang Liu, John A. Wagner, Eseng Lai, David L. Ebel, George Atiee, Victor Dishy, Sandra Reilley, Jane Royalty, John F. Paolini

Publikováno v: The Journal of Clinical Pharmacology. 49:416-422

Niacin is an effective lipid-modifying therapy whose use has been limited by suboptimal tolerability. The adverse effect of flushing is due to prostaglandin D2 (PGD2)-mediated cutaneous vasodilation. Adjunctive treatment with the PGD2 receptor antago

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5aa47b0fedf201af77c7b51ec983c90c
https://doi.org/10.1177/0091270009332246

Zobrazit plný text záznamu

Metabolism And Excretion of the Dipeptidyl Peptidase 4 Inhibitor [14C]Sitagliptin in Humans

Autor: Keith Gottesdiener, David L. Ebel, Kenneth C. Lasseter, Wei Zeng, John A. Wagner, Li Chen, Gary A. Herman, Charles S. Elmore, Bing Zhu, James R. Reed, Patrick J. Larson, Arthur J. Bergman, Stacy C. Dilzer, Stella H. Vincent, Shiyao Xu

Publikováno v: Drug Metabolism and Disposition. 35:533-538

The metabolism and excretion of [(14)C]sitagliptin, an orally active, potent and selective dipeptidyl peptidase 4 inhibitor, were investigated in humans after a single oral dose of 83 mg/193 muCi. Urine, feces, and plasma were collected at regular in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d14b7f45b8ddd9d977decba79d8ea276
https://doi.org/10.1124/dmd.106.013136

Zobrazit plný text záznamu

Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers

Autor: Gary A. Herman, Kenneth C. Lasseter, Stacy C. Dilzer, Wei Zeng, Julie A. Stone, David L. Ebel, Amy Qiu Wang, Li Chen, Arthur J. Bergman, Fang Liu, Rajesh Krishna, John A. Wagner

Publikováno v: Biopharmaceutics & Drug Disposition. 28:315-322

The purpose of this study was to determine the absolute bioavailability of sitagliptin, an orally active, potent and highly selective dipeptidyl peptidase-4 inhibitor recently approved in the United States for the treatment of type 2 diabetes. The ef

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42b8a625600c336d86a0b83e9d267068
https://doi.org/10.1002/bdd.560

Zobrazit plný text záznamu

Lack of Pharmacokinetic Interaction between Rofecoxib and Methotrexate in Rheumatoid Arthritis Patients

Autor: Arturo G. Porras, Jutta L. Miller, David L. Ebel, J. S. Redfern, Gregory B. Holmes, Nancy G. B. Agrawal, Marshall Sack, Jules I. Schwartz, Barry J. Gertz, Kenneth Bachmann, Peggy H. Wong

Publikováno v: The Journal of Clinical Pharmacology. 41:1120-1130

Rofecoxib is a highly selective and potent inhibitor of cyclooxgenase-2 (COX-2). Methotrexate is a disease-modifying agent with a narrow therapeutic index frequently prescribed for the management of rheumatoid arthritis. The objective of this study w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe6782e756422f01f0c919bd916bb13e
https://doi.org/10.1177/00912700122012616

Zobrazit plný text záznamu

Effect of Rofecoxib on the Pharmacokinetics of Digoxin in Healthy Volunteers

Autor: David L. Ebel, Pat J. Larson, Jules I. Schwartz, René Verbesselt, Arturo G. Porras, Simonne Lens, Robert Lins, Barry J. Gertz, Marina De Smet

Publikováno v: The Journal of Clinical Pharmacology. 41:107-112

The authors examined the effect of the cyclooxygenase-2 (COX-2) inhibitor, rofecoxib, at steady state on the pharmacokinetics of digoxin following a single dose in healthy subjects. Each healthy subject (N = 10) received rofecoxib (75 mg once daily)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::685315ba48106602990a377ac48c7e68
https://doi.org/10.1177/00912700122009755

Zobrazit plný text záznamu

MK-386, an Inhibitor of 5α-Reductase Type 1, Reduces Dihydrotestosterone Concentrations in Serum and Sebum without Affecting Dihydrotestosterone Concentrations in Semen1

Autor: Daniel Z. Wang, Jules I. Schwartz, David L. Ebel, Lori A. Geissler, Barry Hafkin, Barry J. Gertz, Aimee Dallob, Wesley Tanaka

Publikováno v: The Journal of Clinical Endocrinology & Metabolism. 82:1373-1377

Two isozymes (types 1 and 2) of 5α-reductase (5αR; EC 1.3.99.5), with differential tissue distribution, catalyze the reduction of testosterone (T) to dihydrotestosterone (DHT) in humans. This study examined sequentially increasing oral doses of MK-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::828671605fcf3f4856850dfd436f88bf
https://doi.org/10.1210/jcem.82.5.3912

Zobrazit plný text záznamu

Novel Oral Medication Delivery System for Famotidine

Autor: Marc L. Berger, Ronald Han, Kuang C. Yeh, Monica E. Hoover, Jules I. Schwartz, Lisa Tomasko, Laura A. Stauffer, David L. Ebel, Thorir D. Bjornsson

Publikováno v: The Journal of Clinical Pharmacology. 35:362-367

A famotidine wafer that rapidly disperses on the tongue without water is a novel alternative to other histamine2 (H2)-antagonist dosage forms. Benefits associated with such a dosage form include convenience and potentially improved compliance for pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c2c18638406839f7fb2a5b5000a7b8d
https://doi.org/10.1002/j.1552-4604.1995.tb04074.x

Zobrazit plný text záznamu

[Untitled]

Autor: Gaylen M. Zentner, Gregory A. McClelland, Gerald S. Rork, James D. Pipkin, Lida Liu, Amy R. Coulter, J. Douglas Rogers, Michael S. Schwartz, Steven C. Sutton, Raju D. Amin, Jules I. Schwartz, Yale B. Mitchel, Haiyung Cheng, Chung Y. Lui, Kenneth Grasing, David L. Ebel, Karen Engle

Publikováno v: Pharmaceutical Research. 10:1683-1687

Seven sustained/controlled-release dosage forms were designed for gastrointestinal delivery of lovastatin or simvastatin, two potent HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia. The in vivo performance of these formulations

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7ecfdb7add32dac2ed025e3ebb2f3d0e
https://doi.org/10.1023/a:1018997308946

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání